Marksans Pharma Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/i05b44obc1thugc4e71ye5ef.pdf

Key Takeaways


Teva Plant Ramp-Up

Mark Saldanha: "we are aiming for INR600-odd crores next year, in next financial year. So, we have two phases that we are, like I mentioned, we are talking of, I think in March we'll be hitting an all-time high, but that's not a great achievement compared to what historically Teva was doing."

Margin Drivers & Sustainability

Mark Saldanha: "I do believe sustainability is a huge possibility. I do believe there is a one-off, so I do believe we should be able to maintain that gross margin part of it."

Geographic & Segment Performance

MarketTrendCommentary
US▲ Strong growthNew product launches, bigger market share, penetrating new retailers; core strength products maturing and growing.
UK▲ Robust growthPortfolio product mix and new product launches driving expansion; matured market so new launches achieve penetration faster. Growth expected to remain robust for the next couple of years.
Australia▼ MutedTiming of approvals and post-COVID distribution channel flooding; season less inductive compared to historic seasons. Plan to be on track next financial year.
Mark Saldanha: "The market size is huge, and I think we are just at the top of the iceberg for us."

Product Pipeline & Backward Integration

Mark Saldanha: "These products are little niche products, high value products, great bottom lines. They are not, they will not be driving the top line, but as a basket collectively, the top line will basically, will grow."

Capital Allocation & Expansion

Mark Saldanha: "Right now we have not shown any plans, although they are looking for an extension, but we are not inclined to accept that extension because we have our own objectives to achieve."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetCross INR3,000 croresWithin the next two years
Teva plant Phase 1 capacity360 crore tablets per annum run rateBy March
Teva plant Phase 2 capacityOver 600 crore tablets per annumMiddle or end of next financial year
Teva plant incremental revenueINR600-odd crores additional revenueFY25
Total capex (FY24 + FY25)INR250 to INR300 croresOver two years
Second DMF filingFile second DMFWithin this quarter
UK new filings34 new filingsNext two years
Effective tax rate24% to 25%Going forward
R&D spendSlightly over 2% of salesOngoing

Key Metrics

MetricQ3 FY24
Operating revenue₹586 cr, +22% YoY vs ₹479 cr
US & North America revenue₹257 cr, +18% YoY
UK & EU revenue₹251 cr, +34% YoY
Australia & New Zealand revenue₹48.6 cr
Rest of world revenue₹29.1 cr
Gross margin53.5%, +336 bps YoY from 50.1%
EBITDA₹133 cr, +73.6% YoY and +16.8% QoQ
EBITDA margin22.7%
Profit after tax₹83 cr, +33.2% YoY and -1.1% QoQ
EPS₹1.84
9M FY24 operating revenue₹1,617 cr, +18.4% YoY vs ₹1,366 cr
9M FY24 EBITDA margin21.6%
9M FY24 PAT₹237.3 cr, +29.9% YoY vs ₹182.6 cr
9M net cash from operations₹169 cr
9M capex incurred₹160.6 cr
9M R&D spend₹29.4 cr, 1.8% of sales
Cash balance₹688 cr as of Dec 31, 2023, debt-free
UK OTC vs Rx split60% OTC, 40% Rx
US OTC vs Rx split75% OTC, 25% Rx
Teva plant Phase 1 capacity targetOver 360 cr units per annum, trending towards by March 2024
Teva plant Phase 2 capacity targetOver 600 cr tablets per annum, anticipated middle or end of FY25
Teva plant FY25 revenue target~₹600 cr, mainly incremental
UK new filings planned34 in next two years
Depreciation benchmark₹22 cr per quarter going forward
Effective tax rate guidance24%–25% going forward
FY24 top line estimate₹2,200-odd cr (per an analyst's math)